SCHEMBL2410002

SCHEMBL2410002

COc1ccc(OC)c(Cc2n[nH]c3c2c(=O)n(-c2ccccc2)c2ncccc32)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE1A P54750 1/20 0.46
PDE1B Q01064 1/20 0.46
PDE4A P27815 3/20 0.40
PDE4B Q07343 3/20 0.40
PDE4C Q08493 3/20 0.40
PDE4D Q08499 3/20 0.40
LIPG Q9Y5X9 1/20 0.40
AR P10275 1/20 0.39
PDE10A Q9Y233 1/20 0.39
MAPT P10636 1/20 0.39
HSP90AB1 P08238 1/20 0.39
MAPK8 P45983 2/20 0.39
MMP10 P09238 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MDM2 Q00987 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2415126 0.93 PDE1A (0.46) PDE1APDE1BPDE4APDE4BPDE4C
SCHEMBL2411012 0.90 AR (0.50) PDE1APDE1BPDE4APDE4BPDE4C
SCHEMBL2408536 0.86 PDE1A (0.55) PDE1APDE1BPDE4APDE4BPDE4C
SCHEMBL2411232 0.86 CYP3A4 (0.53) PDE1APDE1BPDE4APDE4BPDE4C
SCHEMBL2411440 0.86 PDE1A (0.52) PDE1APDE1BPDE4APDE4BPDE4C
SCHEMBL2409708 0.85 PDE1A (0.52) PDE1APDE1BPDE4APDE4BPDE4C
SCHEMBL2411594 0.84 PDE1A (0.55) PDE1APDE1BPDE4APDE4BPDE4C
SCHEMBL4192191 0.82 ADORA2A (0.42) PDE1APDE1BPDE4APDE4BPDE4C
SCHEMBL4197140 0.81 AR (0.43) PDE1APDE1BPDE4BPDE4DAR
SCHEMBL4189450 0.80 PDE1A (0.53) PDE1APDE1BPDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559716-B1 PYRAZOLONAPHTHYRIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2011-09-14 EP claimed
US-20100093782-A1 Pyrazolonaphthyridine derivatives KANAZAWA HASHIME 2010-04-15 US claimed
EP-1559716-A1 PYRAZOLONAPHTHYRIDINE DERIVATIVE Grelan Pharmaceutical Co., Ltd. (JP) 2005-08-03 EP claimed
EP-1559716-B1 PYRAZOLONAPHTHYRIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2011-09-14 EP disclosed
US-20100093782-A1 Pyrazolonaphthyridine derivatives KANAZAWA HASHIME 2010-04-15 US disclosed
US-7608716-B2 Pyrazolonaphthyridine derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-10-27 US disclosed
US-20060040972-A1 Pyrazolonaphthyridine derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2006-02-23 US disclosed
EP-1559716-A1 PYRAZOLONAPHTHYRIDINE DERIVATIVE Grelan Pharmaceutical Co., Ltd. (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040972-A1 Pyrazolonaphthyridine derivative PDE3B, PDE3A, PDE4A PDE1A 28/4885PDE1B 24/4885PDE4A 3/4885
US-20100093782-A1 Pyrazolonaphthyridine derivatives PDE3B, PDE3A, PDE4A PDE1A 30/4885PDE1B 23/4885PDE4A 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.